{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/URGN/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-15T08:40:41.970Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":1466,"canonical_name":"UroGen Pharma Ltd.","cik":"0001668243","uei":null,"lei":null,"duns":null,"ticker":"URGN"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":36,"clinical":1},"count":37,"timeline":[{"ts":"2026-10-09","kind":"sec.filing","form_type":"144","title":"144 — UroGen Pharma Ltd. — 2026-10-09","url_slug":"/sec/cik-0001668243/144/0001976408-26-000887","accession_number":"0001976408-26-000887","importance":30},{"ts":"2026-10-09","kind":"sec.filing","form_type":"4","title":"4 — UroGen Pharma Ltd. — 2026-10-09","url_slug":"/sec/cik-0001668243/4/0001437749-26-032421","accession_number":"0001437749-26-032421","importance":30},{"ts":"2026-09-09","kind":"sec.filing","form_type":"144","title":"144 — UroGen Pharma Ltd. — 2026-09-09","url_slug":"/sec/cik-0001668243/144/0001976408-26-000810","accession_number":"0001976408-26-000810","importance":30},{"ts":"2026-09-09","kind":"sec.filing","form_type":"144","title":"144 — UroGen Pharma Ltd. — 2026-09-09","url_slug":"/sec/cik-0001668243/144/0001976408-26-000811","accession_number":"0001976408-26-000811","importance":30},{"ts":"2026-09-09","kind":"sec.filing","form_type":"4","title":"4 — UroGen Pharma Ltd. — 2026-09-09","url_slug":"/sec/cik-0001668243/4/0001437749-26-029963","accession_number":"0001437749-26-029963","importance":30},{"ts":"2026-09-09","kind":"sec.filing","form_type":"4","title":"4 — UroGen Pharma Ltd. — 2026-09-09","url_slug":"/sec/cik-0001668243/4/0001437749-26-029965","accession_number":"0001437749-26-029965","importance":30},{"ts":"2026-08-28","kind":"sec.filing","form_type":"4","title":"4 — UroGen Pharma Ltd. — 2026-08-28","url_slug":"/sec/cik-0001668243/4/0001437749-26-029175","accession_number":"0001437749-26-029175","importance":30},{"ts":"2026-08-24","kind":"sec.filing","form_type":"4","title":"4 — UroGen Pharma Ltd. — 2026-08-24","url_slug":"/sec/cik-0001668243/4/0001437749-26-028840","accession_number":"0001437749-26-028840","importance":30},{"ts":"2026-08-20","kind":"sec.filing","form_type":"8-K","title":"8-K — UroGen Pharma Ltd. — 2026-08-20","url_slug":"/sec/cik-0001668243/8-k/0001437749-26-028590","accession_number":"0001437749-26-028590","importance":35},{"ts":"2026-08-20","kind":"sec.filing","form_type":"144","title":"144 — UroGen Pharma Ltd. — 2026-08-20","url_slug":"/sec/cik-0001668243/144/0001000275-26-000100","accession_number":"0001000275-26-000100","importance":30},{"ts":"2026-08-12","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — UroGen Pharma Ltd. — 2026-08-12","url_slug":"/sec/cik-0001668243/schedule-13g-a/0000947263-26-000072","accession_number":"0000947263-26-000072","importance":30},{"ts":"2026-08-05","kind":"sec.filing","form_type":"10-Q","title":"10-Q — UroGen Pharma Ltd. — 2026-08-05","url_slug":"/sec/cik-0001668243/10-q/0001437749-26-025794","accession_number":"0001437749-26-025794","importance":45},{"ts":"2026-08-05","kind":"sec.filing","form_type":"8-K","title":"8-K — UroGen Pharma Ltd. — 2026-08-05","url_slug":"/sec/cik-0001668243/8-k/0001437749-26-025793","accession_number":"0001437749-26-025793","importance":35},{"ts":"2026-07-10","kind":"sec.filing","form_type":"4","title":"4 — UroGen Pharma Ltd. — 2026-07-10","url_slug":"/sec/cik-0001668243/4/0001437749-26-023290","accession_number":"0001437749-26-023290","importance":30},{"ts":"2026-07-09","kind":"sec.form144","reporter":"Schoenberg Mark","title":"Officer","shares":10000,"usd_value":400008,"security_title":"COMMON","approx_sale_date":"2026-07-09","accession_number":"0001000275-26-000093","importance":40.0800016},{"ts":"2026-07-09","kind":"sec.insider.s","reporter":"Schoenberg Mark","title":"Chief Medical Officer","shares":10000,"price_per_share":40,"usd_value":400000,"security_title":"Ordinary Shares","importance":35.4},{"ts":"2026-07-09","kind":"sec.filing","form_type":"144","title":"144 — UroGen Pharma Ltd. — 2026-07-09","url_slug":"/sec/cik-0001668243/144/0001000275-26-000093","accession_number":"0001000275-26-000093","importance":30},{"ts":"2026-06-24","kind":"sec.filing","form_type":"4","title":"4 — UroGen Pharma Ltd. — 2026-06-24","url_slug":"/sec/cik-0001668243/4/0001437749-26-021511","accession_number":"0001437749-26-021511","importance":30},{"ts":"2026-06-24","kind":"sec.filing","form_type":"4","title":"4 — UroGen Pharma Ltd. — 2026-06-24","url_slug":"/sec/cik-0001668243/4/0001437749-26-021515","accession_number":"0001437749-26-021515","importance":30},{"ts":"2026-06-24","kind":"sec.filing","form_type":"4","title":"4 — UroGen Pharma Ltd. — 2026-06-24","url_slug":"/sec/cik-0001668243/4/0001437749-26-021517","accession_number":"0001437749-26-021517","importance":30},{"ts":"2026-06-24","kind":"sec.filing","form_type":"4","title":"4 — UroGen Pharma Ltd. — 2026-06-24","url_slug":"/sec/cik-0001668243/4/0001437749-26-021519","accession_number":"0001437749-26-021519","importance":30},{"ts":"2026-06-24","kind":"sec.filing","form_type":"4","title":"4 — UroGen Pharma Ltd. — 2026-06-24","url_slug":"/sec/cik-0001668243/4/0001437749-26-021523","accession_number":"0001437749-26-021523","importance":30},{"ts":"2026-06-22","kind":"sec.form144","reporter":"Schoenberg Mark","title":"Officer","shares":10000,"usd_value":350143,"security_title":"COMMON","approx_sale_date":"2026-06-22","accession_number":"0001000275-26-000079","importance":40.0700286},{"ts":"2026-06-22","kind":"sec.insider.s","reporter":"Schoenberg Mark","title":"Chief Medical Officer","shares":10000,"price_per_share":35.01,"usd_value":350100,"security_title":"Ordinary Shares","importance":35.3501},{"ts":"2026-06-22","kind":"sec.filing","form_type":"144","title":"144 — UroGen Pharma Ltd. — 2026-06-22","url_slug":"/sec/cik-0001668243/144/0001000275-26-000079","accession_number":"0001000275-26-000079","importance":30},{"ts":"2026-06-09","kind":"sec.form144","reporter":"Schoenberg Mark","title":"Officer","shares":5222,"usd_value":140211,"security_title":"Ordinary shares","approx_sale_date":"2026-06-08","accession_number":"0001976408-26-000558","importance":40.02804214},{"ts":"2026-06-09","kind":"sec.filing","form_type":"144","title":"144 — UroGen Pharma Ltd. — 2026-06-09","url_slug":"/sec/cik-0001668243/144/0001976408-26-000558","accession_number":"0001976408-26-000558","importance":30},{"ts":"2026-06-09","kind":"sec.filing","form_type":"4","title":"4 — UroGen Pharma Ltd. — 2026-06-09","url_slug":"/sec/cik-0001668243/4/0001437749-26-019964","accession_number":"0001437749-26-019964","importance":30},{"ts":"2026-06-08","kind":"sec.insider.s","reporter":"Schoenberg Mark","title":"Chief Medical Officer","shares":5222,"price_per_share":27.3,"usd_value":142561,"security_title":"Ordinary Shares","importance":35.1425606},{"ts":"2026-06-08","kind":"sec.insider.m","reporter":"Schoenberg Mark","title":"Chief Medical Officer","shares":10000,"price_per_share":null,"usd_value":0,"security_title":"Ordinary Shares","importance":15},{"ts":"2026-06-02","kind":"sec.filing","form_type":"8-K","title":"8-K — UroGen Pharma Ltd. — 2026-06-02","url_slug":"/sec/cik-0001668243/8-k/0001437749-26-019102","accession_number":"0001437749-26-019102","importance":35},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — UroGen Pharma Ltd. — 2026-05-15","url_slug":"/sec/cik-0001668243/schedule-13g/0000947263-26-000047","accession_number":"0000947263-26-000047","importance":55},{"ts":"2026-05-15","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — UroGen Pharma Ltd. — 2026-05-15","url_slug":"/sec/cik-0001668243/schedule-13g-a/0001104659-26-062615","accession_number":"0001104659-26-062615","importance":30},{"ts":"2026-05-11","kind":"clinical.trial","reporter":"UroGen Pharma Ltd.","title":"A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05243550","excerpt":"[\"Bladder Cancer\",\"Urothelial Carcinoma\",\"Urothelial Carcinoma Bladder\"]","importance":60},{"ts":"2026-05-08","kind":"sec.form144","reporter":"Schoenberg Mark","title":"Officer","shares":10000,"usd_value":300048,"security_title":"COMMON","approx_sale_date":"2026-05-08","accession_number":"0001000275-26-000047","importance":40.0600096},{"ts":"2026-05-08","kind":"sec.filing","form_type":"144","title":"144 — UroGen Pharma Ltd. — 2026-05-08","url_slug":"/sec/cik-0001668243/144/0001000275-26-000047","accession_number":"0001000275-26-000047","importance":30},{"ts":"2026-04-27","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — UroGen Pharma Ltd. — 2026-04-27","url_slug":"/sec/cik-0001668243/schedule-13g/0002012383-26-001661","accession_number":"0002012383-26-001661","importance":55}]}